Westbourne River Partners letter to Biotest AG with respect to the delisting offer made by Grifols SA to shareholders of Biotest.

LONDON, April 15, 2025 /PRNewswire/ -- Westbourne River Partners letter to Biotest AG with respect to the delisting offer made by Grifols S.A. to shareholders of Biotest: Biotest AG Attn.

Ad-hoc RELEASE Announcement according to Article 17 European Market Abuse Regulation (MAR) Biotest AG: Delisting agreement and announced delisting tender offer eieich, March 31, 2025: Biotest AG (ISIN ...

EQS-News: Biotest AG / Key word (s): Annual Report Biotest AG increases sales by 6% in financial year 2024 31.03.2025 / 07:00 CET/CEST The issuer is solely responsible for the content of this ...

TURKU, FI / ACCESS Newswire / April 15, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Inside Information: BEXMAB Phase II trial met its primary endpoint in treatment-resistant High Risk MDS ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Grifols has filed for US approval of a new drug for rare bleeding disorder acquired fibrinogen deficiency (AFD), which promises to provide a more reliable and easier treatment for patients.

This high-potency omega-3 fish oil supplement from Biotest is the most potent blend on the market, packed with 5500 mg DHA & EPA per serving. We highly recommend this product for anyone looking ...

Fractionation is a mechanical process carried out to separate a certain quantity of mixture. Plasma is the liquid part of blood which is yellowish and holds blood cells. Plasma fractionation is ...

As per Vantage Market Research, the Global Plasma Therapy Market has steadily grown over the years due to its potential to ...